Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
FOLFIRINOX versus gemcitabine bij pancreascarcinoom: resultaten na 5 jaar
nov 2022 | Maag-darm-leveroncologie